24 / 164
284
[REV. MED. CLIN. CONDES - 2015; 26(3) 276-284]
for cystic fibrosis related diabetes: a position statement of the
American Diabetes Association and a clinical practice guideline
of the Cystic Fibrosis Foundation, endorsed by the Pediatric
Endocrine Society. Diabetes Care 2010;33:2697-708
10. De Boeck K , Weren M, Proesmans M, Kerem E.Pancreatitis
among patients with cystic fibrosis: correlation with pancreatic
status and genotype.Pediatrics 2005;115:e463-9.
11. Modolell I, Alvarez A, Guarner L, De Gracia J, Malagelada J.
Gastroinetestinal Lives and Pancreatic Involvement in Adult
Patients with Cystic Fibrosis.Pancreas. 2001; 22:395-99
12. Nash KL, Allison ME, McKeon D, et al . A single centre experience
of liver disease in adults with cystic fibrosis 1995-2006.J Cystic
Fibros 2008;7:252-57
13. Davis PB. Cystic fibosis since 1938. Am J resp Crit Care Med
2006;173:475-82
14. Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson
A. Case-control study of acute renal failure in patients with
cystic fibrosis in the UK. Thorax 2008;63:532-535
15. Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR,Goss CH. Risk
factors for chronic kidney disease in adult with cystic fibrosis.
Am J Respir Criit Care Med 2011;184:1147-52
16. Dodge JA. Male fertility in cystic fibrosis. Lancet 1995; 346:
587-588
17. Sueblinvong V , Whitaker LA. Fertility and pregnancy: common
concerns of the aging cystic fibrosis population. Clin Chest Med
2007;28:433-43
18. Gilljam M, Antoniou M, Shin J,et al. Pregnancy in cystic fibrosis.
Fetal and maternal outcome. Chest 2000;118:85-91.
19. Aris RM, Merkel PA, Bachrach LK, et al . Guide to bone
health and disease in cystic fibrosis. J Clin Endocrinol Metab
2005;90:1888-96.
20. Merkel PA. Rheumatic disease and cystic fibrosis. Arthritis
Rheum 1999; 42:1563-71
21-Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd,
Lowenfels AB. Cancer risk in nontransplanted and transplanted
cystic fibrosis patients :a 10-year study. J Natl Cancer Ins
2003;95:381-87
22. de Jong PA, Ottink MD, Robben SG, et al. .Pulmonary disease
assessment in cystic fibrosis: comparison of CT scoring systems
and value of bronchial and arterial dimensión measurements.
Radiology 2004;231:434-9
23-Yankaskas JR,Marshall BC, Sulfian B, et al Cystic fibrosis adult
care:consensus conference report. Chest 2004;125:1S-39S
24. L. Saiman, J. D. Siegel, J. J. LiPuma, et al. «Infection Prevention
and Control Guideline for Cystic Fibrosis: 2013 Update», Infect.
Control Hosp. Epidemiol., vol. 35, n.o S1, pp. S1-S67, ago. 2014
25. J. M. Bhatt, «Treatment of pulmonary exacerbations in cystic
fibrosis», Eur. Respir. Rev., vol. 22, n.o 129, pp. 205-216, sep.
2013.
26. M. Barza, J. P. Ioannidis, J. C. Cappelleri, y J. Lau, «Single or
multiple daily doses of aminoglycosides: a meta-analysis»,
BMJ, vol. 312, n.o 7027, pp. 338-345, feb. 1996.
27. Paul A Corris, MD. Lung transplantation for Cystic Fibrosis and
Bronchiectasis.Semin Respir Crit Care Med 2013;34:297-304.
28. Roger D. Yusen et al. The Registry of the International Sciety
for Heart and Lung Transplntation: Thirty-first Adult Lung
and Heart-Lung Transplant Report-2014;Focus Theme:
Retransplantation. J Heart Lung Transplant ,Vol 33.1009-
1024
29. J. B. Orens, M. Estenne, S. Arcasoy et al., “International Guidelines
for the Selection of Lung Transplant Candidates: 2006 Update-A
Consensus Report From the Pulmonary Scientific Council of the
International Society for Heart and Lung Transplantation,” The
Journal of Heart and Lung Transplantation, vol. 25, no. 7, pp.
745–755, 2006.
30. D. Hadjiliadis, M. P. Steele, C. Chaparro et al., “Survival of lung
transplant patients with cystic fibrosis harboring panresistant
bacteria other than Burkholderia cepacia, compared with
patients harboring sensitive bacteria,” The Journal of Heart and
Lung Transplantation, vol. 26, no. 8, pp. 834–838, 2007.
31. Hertz MI. The Registry of the International Society for Heart and
Lung Transplantation—Introduction to the 2012 annual
reports: new leadership, same vision. J Heart Lung Transplant
2012 31(10):1045–1051.
32. P. A. Flume, P. J. Mogayzel, K. A. Robinson, et al. Clinical Practice
Guidelines for Pulmonary Therapies Committee, «Cystic Fibrosis
Pulmonary Guidelines: Treatment of Pulmonary Exacerbations»,
Am. J. Respir. Crit. Care Med., vol. 180, n.o 9, pp. 802-808, nov.
2009.
33. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR Potentiator in
Patiens with Cystic Fibrosis and the G551D Mutation.. N Engl J
Med 2011; 365: 1663-1672.
34. Davies JC, Wainwright CE, Canny GJ, et al.Efficacy and safety
of ivacaftor in patients aged 6 to 11 years with cystic fibrosis
with a G551D mutation. Am J Respir Crit Care Med 2013; 187:
1219-1225
35. JP Clancy, Rowe SM, Accurso FJ, et al. Results of a phase IIa
study of VX-809, an investigational CFTR corrector compound,
in subjects with cystic fibrosis homozygous for the F508del-
CFTR mutation. Thorax 2012; 67: 12-8.
36. Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol Tetrasodium
in Patients with Cystic Fibrosis and Normal to Mildly Impaired
Lung Function. Am J Respir Crit Care Med 2011; 183: 627-34.